Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why

ACADIA Pharma

Dynavax Technologies

Gilead Sciences

Ligand Pharmaceuticals

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

First-mover advantages are a big deal in the world of pharmaceuticals. CRISPR Therapeutics scored the first-ever regulatory approval for a CRISPR/Cas9 treatment this month.

Is CRISPR Therapeutics the Best Gene-Editing Stock?

Axsome Therapeutics

Moderna

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies and hold onto those shares for the long term.

3 Biotech Stocks That Could Be Millionaire Makers

Applied Optoelectronics

Golden Heaven Group Holdings Ltd

Vertex Pharmaceuticals

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

These Stocks Are Exploding In The November Stock Market Rally

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade

Clearsign Combustion

QuantumScape

The hype around artificial intelligence has settled down a bit lately as people get used to the technology, but there's still a fascination with what these systems can do. One area of great interest is using AI to pick stocks.

Google's Bard AI Says These 3 Stocks Will Rise 1,000%

CRISPR Therapeutics is on the rise after scoring the world's first authorization for a CRISPR-based gene editing treatment. The product, a potentially curative option for hard-to-treat blood disorders, could become a blockbuster.

Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?

Beam Therapeutics

Sarepta Therapeutics

Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare genetic diseases.

3 Monster Stocks in the Making

CRISPR Therapeutics stock continued to rise after the company received U.K. approval for Casgevy (exa-cel). The company and its partner, Vertex Pharmaceuticals, could have more good news on the way.

Why CRISPR Therapeutics Stock Is Jumping Again Today

Archer Aviation

Palantir Technologies

Cathie Wood is as bullish as ever, but recent economic indicators point to strength for her favorite stocks. In an interview, Cathie Wood emphasized that deflation is now a key concern rather than inflation.

3 Cathie Wood You'll Regret Not Buying Soon: November 2023

CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.

CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy

In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug

Shares of Crispr Therapeutics CRSP, +1.68% and Vertex Pharmaceuticals Inc. VRTX, -5.57% gained ground premarket on Thursday after the companies got the world's first regulatory authorization for a medicine based on CRISPR, the transformative gene-editing technology.

Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicine

CRISPR Therapeutics (NASDAQ: CRSP ) stock rose 5% on news the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It's the first authorization in the world for the CRISPR gene-editing technology.

CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy

Crispr Therapeutics (NASDAQ: CRSP) stock price will be in the spotlight on Thursday after the company made a major breakthrough in the UK. The shares surged to a multi-month high of $60 in the pre-market session.

Crispr Therapeutics (CRSP) stock price is on the cusp of a 25% pop

CRISPR Therapeutics shares have advanced this year, but they're still far from their peak. The company is heading for its biggest moment ever: potential product approval.

Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take.

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY has been authorized.

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

ChargePoint Holdings

Medtronic

Rocket Lab USA

SharkNinja Inc

Tilray Brands

One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor interest before falling back to Earth.

Invest in the Future With These 7 Forever Stocks

Arcutis Biotherapeutics

2Seventy Bio

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

3 Biotech Stocks With Key Catalysts Coming in December

Amazon

Growth stocks could lead this latest market rally -- and may deliver growth to your portfolio over time. Amazon and CRISPR Therapeutics are well positioned to benefit from the next bull market.

2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher

Incyte

Shockwave Medical

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical trials, as companies with early stage drugs are too risky for me.

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.

1 No-Brainer Stock to Buy and Hold for 10 Years

Editas Medicine

Intellia Therapeutics

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

Exelixis

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.

News for CRISPR Therapeutics Stock (CRSP)